Hot Topics: Covalent Drug Discovery 2024
Event
BMCS Hot Topics: Covalent Drug Discovery
Dates
Thursday 16th May, 2024 (afternoon)
Place
Online event
Important links and downloads
X Hashtag – #HotTopicsCDD24
To download the first announcement poster, click here
To download the second announcement poster, click here
Synopsis
Covalent binding has emerged as a key strategy in contemporary drug discovery. This online, half-day meeting will bring together experts from both academia and industry to discuss recent advances in using covalent small molecules to target challenging protein targets.
The BMCS Hot Topics online meetings are intended to highlight breaking areas of research in fields of science relevant to drug discovery. They will run as stand-alone half-day virtual events, 2-3 times per year. The programme will be targeted towards researchers working who would like to enhance their understanding of these nascent or developing fields.
Registration
Registration is now closed.
RSC Member* £35
Non-Member £65
RSC Student** Member* £25
Student** Non-Member £40
* Member is a paid-up member of the RSC
** Student rates apply to undergraduate and post-graduate students only, but not post-doctoral students.
Want to become a member?
To join the RSC in order to qualify for discounted registration fees at all RSC, please follow this RSC link.
Sponsorship
The organising committee are seeking sponsorship from organisations supporting the low registration fees offered to students.
Programme
| Chair: Harriet Riley, RSC | |
| 13:00 | Opening Remarks |
|
13:05
|
Targeted Covalent Ligands to address Drug Discovery Challenges Elena De Vita, Queen Mary University of London |
|
13:40
|
Development of AZ’s Covalent Hit-Identification Platform Simon Lucas, AstraZeneca |
| 14:15 | Break |
|
14:30
|
Mechanism of action and therapeutic potential of covalent LSD1 inhibitors Tamara Maes, Oryzon Genomics, Spain |
|
15:00
|
Reimagining Druggability using Chemoproteomic Platforms Dan Nomura, University of California, USA |
| 15:45 | Break |
|
16:00
|
Covalent Drug Discovery – Beyond Cysteine Targeting Lyn Jones, Dana-Farber Cancer Institute, USA |
|
16:45
|
Inhibiting KRAS: Strategies, Structures, and Lessons Learned in the Invention of Sotorasib Brian Lanman, Amgen |
| 17:30 | Close |
With thanks to our sponsors for the meeting
Organising Committee
Adrian Hall, UCB
Daniel O Donovan, AstraZeneca
Harriet Riley, RSC
Chris Swain, Cambridge MedChem Consulting
Secretariat Contact
Hg3 Conferences Ltd
+44 (0)1423 529333
E-mail
